Abstract Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and
completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive …

This systematic review assesses current molecular targeted therapies for glioblastoma
multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA …

The high-mobility group–box transcription factor sex-determining region Y–box 2 (Sox2) is
essential for the maintenance of stem cells from early development to adult tissues. Sox2 …

Stem and progenitor cells are characterized by their ability to self-renew and produce
differentiated progeny. A fine balance between these processes is achieved through …

Glioblastoma (GBM) is an aggressive central nervous system cancer with a dismal
prognosis. The standard of care involves surgical resection followed by radiotherapy and …

Competitive BET bromodomain inhibitors (BBIs) targeting BET proteins (BRD2, BRD3,
BRD4, and BRDT) show promising preclinical activities against brain cancers. However, the …

In addition to each of the factors that govern the identification of a successful oncology drug
candidate, drug discovery aimed at treating neurological cancer must also consider the …

Glioblastomas (GBM) are associated with high rates of relapse. These brain tumors are often
resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment …

SOX2 is a transcription factor involved in multiple stages of embryonic development. In
related reports, SOX2 was found to be abnormally expressed in tumor tissues and correlated …

For the first time, a subset of small cancer cells identified in acute myeloid leukemia has
been termed Cancer Stem Cells (CSCs). These cells are notorious for their robust …